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Abstract 
Liver sinusoidal endothelial cells (LSECs) are involved in the transport of nutrients, 
lipids, and lipoproteins, and LSEC injury occurs in various liver diseases including 
nonalcoholic fatty liver disease (NAFLD). However, the association between LSEC 
injury and NAFLD progression remains elusive. Accordingly, in this study, we aimed to 
elucidate the precise role of LSEC in the pathophysiology of NAFLD using two 
different mouse models, namely the choline-deficient, L-amino acid-defined (CDAA) 
and high fat diet (HFD) models. Administrations of these diets resulted in liver 
metabolic dysregulation mimicking human NAFLD, such as steatosis, ballooning, 
lobular inflammation, and fibrosis, as well as central obesity, insulin resistance, and 
hyperlipidemia. LSEC injury appeared from the simple steatosis phase, and preceded 
the appearance of activated Kupffer cells and hepatic stellate cells. These results 
indicate that LSEC injury may play a “gatekeeper” role in the progression from simple 
steatosis to the early nonalcoholic steatohepatitis (NASH) stage, and LSEC injury may 
be necessary for the activation of Kupffer cells and hepatic stellate cells, which in turn 
results in the development and perpetuation of chronic liver injuries. Taken together, our 
data provide new insights into the role of LSEC injury in NAFLD/NASH pathogenesis. 
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Nonalcoholic fatty liver disease (NAFLD) is one of the manifestations of metabolic 
syndrome, and its worldwide prevalence is continually increasing [1]. NAFLD ranges 
from simple steatosis, which follows a relatively benign course, to nonalcoholic 
steatohepatitis (NASH), which is a more severe form, and which can lead to fibrosis, 
cirrhosis, and, eventually, to hepatocellular carcinoma. Therefore, early diagnosis and 
management of NASH is important for improving the patient prognosis [2], and better 
understanding of NAFLD pathogenesis, particularly in the early stage, is thus essential 
for developing novel strategies for the diagnosis, prevention, and treatment of NAFLD. 
Liver sinusoidal endothelial cells (LSECs) are the most abundant non-parenchymal 
cells in the liver and play important role in the transfer of nutrients, lipids, and 
lipoproteins. Under physiological conditions, LSECs are perforated by fenestrations and 
lack a basement membrane [3]; however, under pathological conditions, LSECs lose 
their fenestrations and form a continuous basement membrane [4]. This phenomenon is 
called “capillarization” as both these features are considered normal structures of the 
capillaries in other organs [5]. It has been demonstrated that sinusoidal capillarization 
precedes liver fibrosis in various liver diseases, including NAFLD [6-7], and our 
previous study using a cholangiopathy model also demonstrated that capillarization 
appeared prior to liver fibrosis [8]. Furthermore, Xie et al. recently reported that 
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capillarization plays a pivotal role in hepatic stellate cell (HSC) activation and 
fibrogenesis during the late stage in a rat liver fibrosis model [9], and LSECs have been 
speculated to play an anti-inflammatory role in cooperation with Kupffer cells, and to 
play a pivotal role for fibrogenesis by promoting HSC activation [10-12]. However, the 
relationship between sinusoidal capillarization and NAFLD progression, and the 
interactions of LSECs with these cells in the different stages of NAFLD remain largely 
unknown. 
In this study, we aimed to clarify the association between LSEC injury and 
NAFLD/NASH progression using the choline-deficient, L-amino acid-defined (CDAA) 
and high fat diet (HFD) models of NAFLD. In addition, we aimed to emphasize the 
importance of the interplay among LSECs, hepatocytes, Kupffer cells, and HSCs in 
order to expand our understanding of the pathogenesis of chronic liver diseases. 
 
MATERIALS AND METHODS 
Animals 
Male C57BL/6 mice (CLEA Japan Inc., Tokyo, Japan) (8 weeks old, weighing 20-25 g) 
were used for all experiments. There is no single animal model of NAFLD completely 
reflecting the complexity of human disease [13]. Accordingly, it is important to use at 
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least two separate animal models when studying this disorder. The CDAA diet is a 
well-established nutritional NAFLD model showing rapid and pronounced liver injury 
[14-15]. However, the metabolic profile of the model does not completely reflect all 
properties of NAFLD in terms of other metabolic dysregulations, because hepatic lipid 
accumulation of the model is mainly due to impaired secretion of very low-density 
lipoprotein (VLDL). Therefore, this model is considered suitable for evaluations of 
intrahepatic lesions in severe NASH. On the other hand, the HFD model more closely 
resembles the pathophysiology of human NAFLD with diabetes and central obesity. 
However, this model is requires more time and the hepatic lesions are less marked [13]. 
Thus, the HFD model is well suited for evaluations of capillarization in the early stages 
of NAFLD associated with diabetes and central obesity. In the CDAA mice, to induce 
steatohepatitis, the mice were fed a CDAA diet (Dyets Inc., Bethlehem, PA, USA) for 1, 
4, 8, or 22 weeks. For the regression experiment, another group of animals was fed a 
CDAA diet for 8 weeks and allowed to recover on a standard diet for an additional 4 
weeks. The HFD mice were fed an HFD (Dyets Inc.) for 8 and 22 weeks. The control 
mice were fed a standard diet.  
The experimental animals were sacrificed at each indicated time point. Blood was 
collected by cardiac puncture after fasting for four hours. For light and electron 
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microscopic analyses, the mice were perfused for 1 min with saline and fixed by 
transcardial perfusion (approximately 100 mmHg) with 10% buffered formaldehyde or 
2% glutaraldehyde. At least three mice were treated and analyzed for each time period 
and treatment. All mice were housed in individual cages under specific pathogen-free 
conditions with food and water ad libitum. There was no difference in food intake 
between the groups (data not shown).  
All experimental protocols were approved by the local Animal Care and Use 
Committee, and were performed according to the criteria outlined in the Guide for the 
Care and Use of Laboratory Animals prepared by the National Academy of Sciences, as 
published by the National Institutes of Health [16]. 
 
Serum biochemical analysis 
The serum samples were stored at −80C until the analyses could be performed. The 
alanine aminotransferase (ALT), alkaline phosphatase (ALP), total-cholesterol, 
triglyceride, free fatty acids, total-bilirubin, and glucose levels were analyzed using a 
Hitachi 7180 analyzer (Hitachi, Tokyo, Japan). 
 
Histopathology 
Masashi Miyao 9 
 
Formalin-fixed paraffin-embedded sections were cut 4-μm thick and stained with 
hematoxylin and eosin or Azan. Frozen sections were cut to 10 μm and stained with Oil 
Red O for lipid analysis. A modified histological NAFLD/NASH score, as per the 
recommendations of the Nonalcoholic Steatohepatitis Clinical Research Network, was 
used [17]. Briefly, four histological features were semiquantitatively assessed: steatosis 
(0-3), lobular inflammation (0-3), hepatocellular ballooning (0-2), and fibrosis (0-4). 
The histological features of the specimens were independently assessed by an 
experienced pathologist (MM) and an attending pathologist (HK) in a blinded fashion, 
and a consensus diagnosis was obtained for each sample. To determine the interobserver 
reproducibility of each feature, unweighted kappa coefficients were calculated. The 
results showed good-to-excellent interobserver agreement, as demonstrated by a kappa 
coefficient of 0.72 (good) for steatosis, 0.82 (excellent) for lobular inflammation, 0.72 
(good) for hepatocyte ballooning, and 0.77 (good) for fibrosis. 
 
Immunohistochemical studies 
Immunohistochemical staining of the specimens was performed according to the 
manufacturer’s instructions. Briefly, antigen retrieval was carried out in a pressure 
cooker by boiling in 10 mM citrate buffer (pH 6.0), followed by washing with 
Masashi Miyao 10 
 
phosphate-buffered saline. Subsequently, endogenous peroxidase was quenched with 
3% H2O2 for 10 min at room temperature. After rinsing, the slides were treated 
overnight at 4°C with a negative control reagent or the following optimally diluted 
primary antibodies: cluster of differentiation (CD) 31 (rabbit polyclonal; 1:50; Abcam, 
Cambridge, MA, USA), CD34 (rat monoclonal; 1:200; Abcam), F4/80 (rat monoclonal; 
1:200; Abcam), and α-smooth muscle actin (αSMA; rabbit polyclonal; 1:400; Abcam). 
Next, the slides were incubated with anti-mouse and anti-rabbit horseradish 
peroxidase-conjugated secondary antibody (goat polyclonal; prediluted; MBL, Nagoya, 
Japan). Binding to the antibody was detected using the labeled polymer method. 
Diaminobenzidine was used as the chromogen, followed by counterstaining with 
hematoxylin. For quantitative assessment of protein expression, the staining of each 
immunohistochemical specimen was captured in 10 randomly selected fields at 200× 
magnification and calculated using ImageJ software (US National Institutes of Health, 
Bethesda, MD, USA). 
 
Quantitative reverse transcription polymerase chain reaction 
Total RNA was extracted from liver tissue using TRIzol (Invitrogen, Carlsbad, CA, 
USA). cDNA was synthesized from total RNA using SuperScript III reverse 
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transcriptase (Invitrogen). Real-time PCR was performed using FastStart SYBR Green 
Master (Roche Diagnostics, Basel, Switzerland) and Rotor-Gene Q (Qiagen, Venlo, 
Netherland). The primer pairs are shown in Supplementary Table 1. The relative target 
gene expressions were normalized to GAPDH mRNA expression. 
 
Transmission and scanning electron microscopic analyses 
Perfusion-fixed livers were cut into 1-mm sections for transmission electron microscopy 
(TEM) and into 2-mm sections for scanning electron microscopy (SEM). These sections 
were immersion fixed in 2% glutaraldehyde at 4°C for 2 hours. The specimens for TEM 
were extensively washed with phosphate-buffered saline, postfixed in 1% osmium 
tetroxide, dehydrated in a graded series of ethanol, and embedded in Epon. Ultra-thin 
sections (80 nm) were cut on an Ultra microtome EM UC6 (Leica, Vienna, Austria), 
stained with 1% uranyl acetate, counterstained using the Reynolds method, and 
examined on an H-7650 electron microscope (Hitachi). The specimens for SEM were 
postfixed in 1% osmium tetroxide, dehydrated in a graded series of ethanol, and dried. 
Subsequently, the sections were coated with a thin layer of platinum/palladium and 
visualized under an S-4700 electron microscope (Hitachi). For evaluations of 
capillarization severity, the percent of open space area in the LSECs (porosity) was 
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measured in 15 randomly selected fields at 10 000× magnification on at least three 
animals per group, using ImageJ software. 
 
Statistical analysis 
Data are reported as the arithmetic means ± SEM. All data were analyzed using SPSS 
version 20.0 software (SPSS, Tokyo, Japan). Statistical significance was determined 
using Student’s t test or the Mann-Whitney U test with Bonferroni correction for 




CDAA feeding induces macroscopical steatosis and hepatomegaly during the early 
phase of NAFLD/NASH pathogenesis 
To determine the morphological changes occurring during the early phase of 
CDAA-induced NAFLD/NASH pathogenesis, we obtained tissue samples from the 
mice after up to 8 weeks of CDAA feeding. The CDAA-fed mice showed liver 
enlargement and pale yellow discoloring, indicating hepatic steatosis (Figure 1a). 
Although the body weight of the CDAA-fed mice was similar to that of the controls up 
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to 8 weeks feeding, the liver weight/body weight ratio of the CDAA-fed mice was 
significantly increased from 4 weeks of feeding and onwards, indicating hepatic injury 
and hepatomegaly (Figure 1b). Moreover, the spleen weight/body weight ratio, an 
indicator of portal hypertension, was significantly increased after 8 weeks of the CDAA 
diet. Similarly, the visceral fat weight/body weight ratio was significantly increased in a 
time-dependent manner from 4 weeks of feeding, indicating that the CDAA-fed mice 
were progressing to central obesity. Next, we investigated the functional changes in 
CDAA-diet-induced NAFLD/NASH by serum biochemical analyses. To exclude the 
effects of aging, we compared the control 0-week (8-week-old) with control 8-week 
(16-week-old) mice, and confirmed that there was no significant difference between the 
two control groups in all serum parameters (data not shown). Compared to the control 
mice, the CDAA-fed mice showed significant elevations of serum ALT and glucose 
from 1 week, and bilirubin and ALP levels from 4 weeks (Figure 1c). Interestingly, all 
CDAA-fed mice showed a significant reduction of the serum triglyceride levels, 
whereas no significant differences were observed in the serum cholesterol and free fatty 
acid levels; these findings may be explained by compensatory hepatic uptake of serum 
lipids or by impairment in VLDL secretion from the liver [18-19].  
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CDAA feeding induces microscopical steatosis, intralobular inflammation, and 
pericellular fibrosis during the early to intermediate phase 
To further evaluate the morphological changes in the early phase of the CDAA diet 
model, we performed histopathological examinations of the CDAA-fed mouse livers 
after up to 8 weeks of feeding. Both hematoxylin and eosin and Oil red O staining of the 
liver sections from the CDAA-fed mice revealed steatosis already after 1 week of 
CDAA feeding (Figure 2a and b). At 1 week of CDAA feeding, no significant 
inflammatory infiltration or no significant fibrosis was found; thus, the mice at 1 week 
of CDAA feeding reflect simple steatosis, which represents a very early stage of 
NAFLD/NASH pathogenesis. After hepatic steatosis occurred, intralobular 
inflammation and pericellular fibrosis emerged from 4 weeks of CDAA feeding and 
were aggravated in the period leading up to 8 weeks of feeding, indicating that 4 weeks 
or more of CDAA feeding reflects the intermediate NASH stage (Figure 2a and b). 
Intriguingly, reticulin staining showed a different staining pattern between 4 and 8 
weeks of CDAA feeding: the 4-week CDAA-fed mice showed a thick black staining 
pattern whereas the 8-week CDAA-fed mice showed a combination staining pattern of 
thick and pale black areas (Figure 2a). These different staining patterns may be 
explained by increased maturity of the collagen fibers at 8 weeks, because reticulin 
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tends to stain immature collagen fibers (type III collagen) in thick black, whereas 
mature collagen fibers (type I collagen) stain pale black. 
 
Sinusoidal capillarization appears in the early phase of NAFLD/NASH 
pathogenesis 
To determine when capillarization appears in the NAFLD/NASH pathogenesis, we next 
investigated the LSEC in the CDAA-fed mice up to 8 weeks by SEM, TEM, and 
immunohistochemical analyses. In the control mice, the LSECs exhibited typical 
fenestrae grouped in sieve plates (Figure 3a). In contrast, all LSECs in the CDAA-fed 
mice were overtly defenestrated after up to 8 weeks of feeding, indicating 
capillarization (Figure 3a and Supplementary Figure 1). Quantitative assessment of the 
fenestrated area revealed that the CDAA diet caused approximately 20%, 8-fold, and 
28-fold reductions in porosity after 1, 4, and 8 weeks of feeding, respectively (Figure 
3b). In line with these findings, the expressions of the capillarization markers (CD31 
and CD34) were significantly increased after 4 and 8 weeks CDAA feeding upon 
immunohistochemical analyses (Figure 3c and d).  
 
Activated Kupffer cells and hepatic stellate cells appear after sinusoidal 
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capillarization 
Next, we analyzed the timing of activation of the Kupffer cells and HSCs in the early 
phase of NAFLD/NASH. To achieve this, we assessed the morphological and functional 
changes of these cells by histological and immunohistochemical analyses. Because 
lipids are lost in formalin-fixed paraffin-embedded sections during tissue processing and 
because frozen tissue sample analysis has extremely low-resolution power, we first 
investigated toluidine blue staining semithin sections of resin-embedded specimens. The 
semithin sections revealed that lipogranulomas formed crown-like structures, unique 
histological features of Kupffer cells in NASH but not simple steatosis [20], in the 
intralobular regions after 4 weeks of CDAA feeding (Figure 4a), which were 
exacerbated over time (data not shown). In the TEM analysis, quiescent Kupffer cells 
were seen in the control mice, while large and phagocytic macrophages with extending 
pseudopods were seen in the CDAA-fed mice after 4 weeks (Figure 4b and 
Supplementary Figure 2). In line with these findings, the immunohistochemical analysis 
of F4/80, an activation maker of Kupffer cells, also showed increased intensity of the 
stained area after 4 weeks of CDAA feeding (Figure 4c). After 8 weeks of CDAA 
feeding, macrovesicular lipids encircled by F4/80-positive cells, indicating typical 
crown-like structures, were diffusely found throughout the liver (Figure 4c). Quiescent 
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HSCs, ”fat-storing cells,” were seen in the control mice, whereas spindle-shaped 
collagen-producing cells, myofibroblasts, which may be derived from HSCs, were 
found in the space of Disse from 4 weeks of CDAA feeding (Figure 4b and 
Supplementary Figure 2). Furthermore, immunohistochemical analysis of αSMA, an 
activation marker of HSCs, also displayed increased intensity of the stained area after 4 
weeks of CDAA feeding (Figure 4c). 
To further understand the mechanism of progression from simple steatosis to NASH, 
we next examined the gene expression changes in the early phase of NAFLD by 
quantitative RT-PCR analysis. The mRNA levels of inflammatory cytokines and 
chemokine such as tumor necrosis factor α (TNFα), interleukin-6 (IL-6), and monocyte 
chemotactic protein-1 (MCP-1) were significantly increased after 1 week of CDAA 
feeding, indicating that inflammatory responses and activating Kupffer cells had already 
emerged at the transcriptional level in the simple steatosis phase (Figure 4d). Moreover, 
the mRNA levels of vascular endothelial growth factor receptor 2 (VEGFR2) were 
significantly increased at 4 weeks, while the levels after 1 week of feeding tended to be 
increased, without statistical significance, indicating that LSEC regenerative changes 
appear from the simple steatosis phase to the early NASH phase. In addition, the mRNA 
levels of genes involved in HSC activation and fibrogenesis such as αSMA, tissue 
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inhibitor of metalloproteinase 1 (TIMP1), interleukin-1β (IL-1β), collagen type I α 1 
(Col1α1), and collagen type IV α 1 (Col4α1) were increased after 1 week of feeding, 
indicating that HSC activation and fibrotic responses emerge at the transcriptional level 
already in the simple steatosis phase (Figure 4d). 
Taken together, our results suggest that capillarization is necessary for the appearance 
of activated Kupffer cells and HSCs, although activation of these cells at the 
transcriptional level is initiated already in the simple steatosis stage. 
 
Sinusoidal capillarization is aggravated in the cirrhotic phase and shows partial 
recovery by discontinuation of the experimental diet 
To determine the association between capillarization and disease progression in the late 
phase of the CDAA model, we performed macroscopical, microscopical, and serum 
analyses after 22 weeks of CDAA feeding. In both the macroscopic and histological 
analyses, the livers of the mice exhibited distinctly cirrhotic features, with or without 
hepatocellular adenoma (Figure 5a and Supplementary Figure 3). In line with these 
morphological findings, the serum ALT levels were not obviously increased, whereas 
the levels of ALP and bilirubin remained high, indicating that 22-week CDAA mice 
well reflect the symptoms and signs of the late NASH stage in humans (Table 1). 
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To clarify whether capillarization worsens in the late phase of NAFLD/NASH, we 
next assessed LSEC injury in the 22-week CDAA mice. Significant decreases in 
porosity of approximately 57-fold and 34-fold compared to the control mice at 0 and 22 
weeks, respectively, were observed (Figure 5b and c). It should be noted that the LSEC 
fenestrae decrease can be, however, induced not only by pathologic stresses but also by 
aging, with this decrease in LSEC fenestrae with aging being referred to as 
pseudocapillarization [21]. As expected, although no significant difference in porosity 
was observed between the control 0-week and control 8-week mice (data not shown), 
the control 22-week (30-week-old) mice showed a significant decrease in porosity, 
indicating age-related pseudocapillarization (Figure 5b and c). However, this decrease 
in porosity of the control 22-week mice was negligible compared to that of the CDAA 
22-week mice. 
To determine whether capillarization and other pathogenic features could recover 
after withdrawal of CDAA feeding, mice fed for 8 weeks with the CDAA diet were 
returned to a standard diet for an additional 4 weeks and subsequently analyzed. The 
serum ALT, ALP, and bilirubin levels (Table 1) and all histological grading scores were 
almost completely normalized in these mice, whereas the staging of fibrosis partially 
remained, especially around the lipogranulomas (Figure 6a and b). Additionally, 
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capillarization was also significantly recovered after 4 weeks of cessation of CDAA 
feeding; however, the degree of recovery was lower compared to that of the other 
pathological features (steatosis, inflammation, and hepatocyte ballooning) (Figure 6c 
and d), suggesting that the presence of capillarization upon SEM analysis has extremely 
high sensitivity and specificity in the NAFLD/NASH pathogenesis. 
Prior studies have delineated that differentiated LSECs (fenestrated LSECs) promote 
HSC quiescence and vice versa [9, 22]. Consequently, in the current study, to clarify the 
relationship between LSECs and HSCs, we next analyzed whether HSC quiescence 
occurred after 4 weeks cessation of CDAA feeding, when the LSECs have partially 
returned to a differentiated state. We found that the αSMA-positive cells (activated 
HSCs) had completely disappeared at that time point, and, instead, fat-storing quiescent 
HSCs appeared in the toluidine-stained semithin sections (Supplementary Figure 4). 
These findings indicate that the state of differentiation of LSECs, which represent the 
severity of capillarization, correlates well with NAFLD/NASH disease progression and 
regression. 
 
High fat feeding also shows steatosis with sinusoidal capillarization but without 
severe inflammation and fibrosis 
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In order to exclude that the results of capillarization are confounded by model-specific 
effects and to clarify the association between capillarization and hepatic steatosis, we 
conducted additional experiments using an HFD-fed mouse model, which shows severe 
steatosis but does not induce severe inflammatory and fibrotic changes until in the late 
phase. Macroscopically, both 8-week and 22-week HFD-fed mice showed 
hepatomegaly with pale yellow discoloring (Figure 7a and Table 1) and severe body 
weight and visceral fat weight gains (Table 1). Serum biochemical analyses showed 
significant increases in the cholesterol and glucose levels in both 8-week and 22-week 
HFD-fed mice, well reflecting human metabolic syndrome. Although the serum 
triglyceride level was decreased, this may again be explained by compensatory hepatic 
uptake of serum lipids or by impairment in the VLDL secretion from the liver [18-19]. 
The serum ALT level was increased only in the 22-week HFD-fed mice, whereas the 
serum ALP and bilirubin levels were not greatly increased. Histologically, the HFD 
8-week mice showed hepatic steatosis but no inflammatory and fibrotic changes 
compared to the controls. The HFD 22-week mice showed severe hepatic steatosis and 
significant, but not severe, inflammatory and fibrotic changes (Figure 7b-d). These 
results suggest that the HFD 8-week feeding mouse model mimics the human simple 
steatosis stage whereas the HFD 22-week feeding mice mimic the early NASH stage.  
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We next evaluated whether capillarization occurs in HFD-fed mice using SEM and 
TEM analyses. Capillarization was not detected in HFD 8-week mice but was severe in 
the HFD 22-week mice, as compared to each control (Figure 7e, f and Supplementary 
Figure 5). The severity of capillarization in the HFD 22-week mice was less prominent 
than that of the CDAA 22-week mice. 
Taken together, these results indicate that capillarization may play a “gatekeeper” 
role in the progression from simple steatosis to the early NASH stage, and may 
represent a generalized change in NAFLD/NASH pathogenesis. 
Finally, to determine when intracellular organelle injuries of hepatocyte appear in the 
NAFLD pathogenesis, we analyzed the endoplasmic reticula (ERs), mitochondria, 
autophagosomes and lysosomes, nuclei, and bile canaliculi in both models by TEM. In 
the CDAA mice, enlarged ERs first appeared from 4 weeks of feeding (Supplementary 
Figure 6). Deformed mitochondria and an increase of autophagosomes and lysosomes 
appeared from 8 weeks of feeding, while pseudoinclusion bodies in the nuclei and loss 
of microvilli of bile canaliculi were identified at 22 weeks of feeding. In HFD mice, 
deformed mitochondria first appeared from 8 weeks of feeding. Enlarged ERs, an 
increase of autophagosomes and lysosomes, and pseudoinclusion bodies in the nuclei 
were detected at 22 weeks of feeding (Supplementary Figure 7). No pathological 
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changes were detected in the bile canaliculi of HFD-fed mice. 
 
DISCUSSION 
Capillarization has been known to occur in many different kinds of liver injuries (e.g., 
cirrhosis, hepatitis, alcoholic liver injury, and arsenic poisoning), to influence liver 
regeneration processes, and to naturally increase in severity with age 
(pseudocapillarization); however, the relationship between capillarization and NAFLD 
remains elusive [6, 23-24]. To our knowledge, our comprehensive macroscopical, 
microscopical, ultrastructural, biochemical, and quantitative RT-PCR analyses of two 
distinct NAFLD models are the first to reveal that capillarization arises during the 
progression from simple steatosis to the early NASH stage, and that it worsens in a 
time-dependent manner up until the late stage (Figures 3 and 7). Furthermore, we here 
revealed that the relationship of capillarization with disease progression is not 
model-specific, suggesting that capillarization is a generalized change of 
NAFLD/NASH pathogenesis. These new kinetic understandings of capillarization in the 
NAFLD progression may provide more information for future research efforts on 
NAFLD. Especially, focusing on capillarization may help improve the understanding of 
the initiating mechanisms of NASH in the early stages, and may eventually lead to the 
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discovery of novel strategies for the prevention of disease progression and for 
promotion of disease regression in the late stages. 
Kupffer cells and HSCs have been known to play critical roles in triggering fibrosis 
via monocyte recruitment and excessive collagen production [25]. However, the 
interactions of LSECs with Kupffer cells and HSCs in NAFLD pathogenesis remain 
largely unknown [26]. The current study examined the morphological and functional 
changes of these cells, and showed that both types of cells appeared activated after 
capillarization. In the CDAA model, immunohistochemical analysis of the macrophage 
activation maker F4/80 revealed that the activated Kupffer cells appeared from the early 
NASH phase, and were identified as typical crown-like structures from the intermediate 
NASH phase (Figure 4c). HSCs, differentiated lipid-storing cells found in the space of 
Disse, were identified in the control and simple steatosis phase (CDAA 1-week and 
HFD 8-week mice), but were not observed after the early NASH phase (CDAA 4-week 
and HFD 22-week mice). Meanwhile, from the early NASH phase, instead of 
differentiated HSCs, many dedifferentiated HSCs, spindle-shaped αSMA-positive cells, 
appeared around the necrotic hepatocytes and were found to release excessive collagen 
fibers (Figure 4b, c, and Supplementary Figure 4). In accordance with the observed 
HSC dedifferentiation, pericellular fibrosis appeared from the early phase, and 
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progressed to cirrhosis in the late phase (Figure 5 and Supplementary Figure 3). 
Moreover, the quantitative RT-PCR analysis showed that the mRNA levels involved in 
inflammation and Kupffer cell activation, vascular regeneration, and fibrogenesis and 
HSC activation increased already after 1 week of CDAA feeding, indicating that these 
changes were initiated at the transcriptional level already in the simple steatosis phase 
(Figure 4d). Collectively, these results suggest that capillarization is the earliest 
morphological change in NASH pathogenesis, and that it plays critical roles in hepatic 
inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma development through 
activation of Kupffer cells and HSCs. 
In the current study, we found that various common intracellular organelle injuries 
of hepatocytes appeared after capillarization in both models. First, enlarged ERs, 
deformed mitochondria, and an increase of autophagosomes and lysosomes appeared, 
after which pseudoinclusion bodies in the nuclei and loss of microvilli in the bile 
canaliculi were recognized (Supplementary Figure 6 and 7). These results suggest that 
capillarization due to excessive hepatic lipid accumulation and elevated circulating 
lipids may lead to endoplasmic reticulum stress, mitochondrial dysfunction, 
cytoskeleton alterations, and DNA damages in the hepatocytes. Further studies are 
needed to determine whether sinusoidal capillarization is responsible for these 
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hepatocyte organelle injuries in the NAFLD progression. 
One obvious advantage of diet-induced NAFLD models is the possibility of 
performing regression experiments. In this study, we evaluated the restoration levels of 
individual features of NAFLD following cessation of CDAA administration. 
Macroscopically, CDAA cessation resulted in almost complete recovery in terms of 
body weight and visceral fat; however, the spleen weight (an indicator of portal 
hypertension) remained high (Table 1). Moreover, similar to the results of the 
macroscopical analyses, the microscopical findings of NASH, such as hepatic steatosis, 
intralobular inflammation, and hepatocyte ballooning, were also recovered (Figure 6a 
and b). On the other hand, slight pericellular fibrosis remained around the dead 
hepatocytes, with crystallized lipid droplets, and the restoration of capillarization 
showed only a 40% recovery in porosity (Figure 6c and d). As capillarization and 
pericellular fibrosis are known to be closely related to portal hypertension, our results 
suggest that sinusoidal capillarization is a delaying factor for the healing processes of 
fibrosis, and is a preserving factor of portal hypertension in NAFLD [27-28]. 
In this study, we provided the first evidence showing that capillarization may play a 
“gatekeeper” role in the progression from simple steatosis to the early NASH stage. 
Capillarization may occur prior to overt inflammation in the early stage, and plays a role 
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in fibrogenesis in the late stage as well as delays the healing processes of portal 
hypertension in the recovering stage. Based on our findings herein, we propose the 
following mechanisms of NAFLD/NASH progression: 1) hepatic steatosis with 
proinflammatory and profibrogenic cytokine release occurs due to excessive fat intake 
or as a result of metabolic dysregulation or genetic susceptibility; consequently, 2) 
capillarization appears, followed by 3) definite inflammatory cell infiltrations, 4) 
pericellular fibrosis, and, eventually, 5) cirrhosis and hepatocellular carcinoma. 
There are several clinical implications of the findings reported here. First, assessing 
the severity of LSEC injuries could help distinguish between simple steatosis and the 
early NASH stage, potentially leading to earlier detection of NASH. Second, 
development of drugs that can maintain a differentiated state for LSECs may prevent 
progression and promote recovery of NAFLD/NASH. Third, drugs that influence the 
differentiation state of LSECs may also be applied to the prevention and treatment of 
systemic vascular diseases, especially for atherosclerosis [29], as LSEC injury and 
dyslipidemia secondary to impaired lipid transport by LSEC injury might indirectly 
pertain to the capillary vessels of other organs such as the heart, lungs, and kidneys [3, 
30]. 
A limitation of the present study is that, although we clarified that sinusoidal 
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capillarization correlates well with NAFLD/NASH progression, we did not determine to 
what degree capillarization contributes to NAFLD/NASH progression. Further studies, 
for example focusing on the effects of administrating drugs that influence the restoration 
and capillarization of the LSEC phenotype, could resolve this question. 
In conclusion, the results obtained herein provide new insights into NAFLD/NASH 
pathogenesis. LSEC injuries in the early stage of NAFLD appear to be necessary for the 
activation of Kupffer cells and HSCs, which in turn results in the development and 
perpetuation of chronic liver injuries. This insight may help to elucidate the crosstalk 
among hepatocytes, Kupffer cells, HSCs, and LSECs in NAFLD/NASH progression, 
and to help establish novel strategies for early diagnosis, prevention, and treatment in 
chronic liver diseases.
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Figure legends 
Figure 1: (a) Macroscopic photographs of livers from control and choline-deficient, 
L-amino acid-defined (CDAA) 8-week mice. (b) Body weight, liver/body weight ratio, 
spleen/body weight ratio, and visceral (epididymal) fat/body weight ratio in control 
(white circles) and CDAA-fed mice (black boxes) during the experimental feeding 
period of 8 weeks. Data are presented as means ± SEM. *P <0.05 compared with each 
corresponding time point of the control mice. **P <0.01 compared with the control mice. 
(c) Serum levels of alanine aminotransferase (ALT), fasting blood glucose, alkaline 
phosphatase (ALP), total bilirubin, triglyceride (TG), total cholesterol, and free fatty 
acid (FFA) in control mice (0 weeks; white bar) and CDAA-fed mice (black bar) after 1, 
4, and 8 weeks. *P <0.05 compared with the control (0-week) mice; **P <0.01 compared 
with the control (0-week) mice; NS, not significant. n ≥ 6 for all groups. 
 
Figure 2: (a) Histopathological images of livers from control and choline-deficient, 
L-amino acid-defined (CDAA)-fed mice after 1, 4, and 8 weeks. Hematoxylin and eosin 
(H&E) staining (top row; bars = 100 μm), Oil red O staining (second row; bars = 25 
μm), Azan staining (third row; bars = 50 μm), and reticulin staining (bottom row; bars = 
25 μm) are shown. Arrows indicate inflammatory cell infiltration (steatohepatitis). 
Arrowheads indicate reticulin-positive areas (type III collagen) in the intralobular 
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lesions. pv, portal vein; cv, central vein. (b) Nonalcoholic fatty liver disease activity 
scores (steatosis, inflammation, and ballooning) and fibrosis stage in control and 
CDAA-fed mice after 1, 4, and 8 weeks. Data are presented as means ± SEM. **P <0.01 
compared with the control mice. n ≥ 5 for all groups. N.D, not detected. 
 
Figure 3: (a) Scanning electron microscopic images (top row, low-magnification 
images, bars = 5 μm; bottom row, high-magnification images of boxed areas, bars = 1 
μm) of liver sinusoidal endothelial cells in control and choline-deficient, L-amino 
acid-defined (CDAA)-fed mice after 1, 4, and 8 weeks. Arrows indicate fenestrae 
grouped into sieve plates. Arrowheads indicate gaps. (b) Porosity in control (white bar) 
and CDAA-fed mice (black bar) after 1, 4, and 8 weeks. *P <0.05 compared with the 
control (0-week) mice; **P <0.01 compared with the control. n ≥ 3 for all groups. 
Fifteen random fields (×10 000 magnification) were analyzed for each group. (c) 
Immunohistochemical staining for cluster of differentiation (CD)31 (top row) and CD34 
(bottom row) in control and CDAA-fed mice after 1, 4, and 8 weeks. Asterisks indicate 
the internal positive control-stained areas (Glisson’s capsules). Arrowheads indicate the 
positive areas for each antibody. Bars = 50 μm. (d) Quantitative analyses for each 
antibody-positive area in the control (white bar) and CDAA-fed mice (black bar) after 1, 
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4, and 8 weeks. Data are presented as means ± SEM. *P <0.05 compared with the 
control (0-week) mice; **P <0.01 compared with the controls. Ten random fields were 
analyzed for each group (×200 magnification). 
 
Figure 4: (a) Toluidine blue staining of resin-embedded liver sections for control and 
choline-deficient, L-amino acid-defined (CDAA)-fed mice after 4 weeks. Grey staining 
indicates lipid droplets. Arrowheads indicate hepatic stellate cells (lipid storing cells; Ito 
cells). The arrow indicates lipogranuloma. Bar = 25 μm. (b) Transmission electron 
microscopic images of livers from control and CDAA-fed mice after 4 weeks. Black 
arrowheads (top right panel) indicate elongated pseudopods of Kupffer cell with lipid 
phagocytosis. White arrowheads (bottom right panel) highlight collagen release. Bars = 
5 μm. H, hepatocyte; HSC, hepatic stellate cell; K, Kupffer cell; LSEC, liver sinusoidal 
endothelial cell. (c) Immunohistochemical staining for F4/80 (top row) and α-smooth 
muscle actin (αSMA; bottom row) in control and CDAA-fed mice after 1, 4, and 8 
weeks. Arrowheads indicate positive staining of each antibody. Asterisks indicate the 
internal positive control-stained areas (smooth muscle of arteries). The right panel 
shows the quantitative analyses of each antibody-positive stained area in control (white 
bar) and CDAA-fed mice (black bar) after 1, 4, and 8 weeks. Data are presented as 
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means ± SEM. **P <0.01 compared with the control (0-week) mice; ***P <0.001 
compared with the controls. Ten random fields were analyzed for each group (×200 
magnification). (d) Quantitative RT-PCR analysis in control and CDAA-fed mice after 1 
and 4 weeks. Values are normalized to GAPDH expression and are presented as means 
± SEM. *P <0.05 compared with the control (0-week) mice; **P <0.01 compared with 
the control; ***P <0.001 compared with the control. 
 
Figure 5: (a) Macroscopic photographs of livers from control 22-week and 
choline-deficient, L-amino acid-defined (CDAA) 22-week mice. The CDAA-fed mice 
showed atrophic livers with rough surfaces and pale yellow discoloring, indicating 
cirrhosis. (b) Scanning electron microscopic images of liver sinusoidal endothelial cells 
in control 0-week, control 22-week, and CDAA 22-week mice. Arrowheads indicate 
fenestrae grouped into sieve plates. Asterisks indicate collagen deposits in the space of 
Disse. Bars = 1 μm. (c) Porosity in control 0-week, control 22-week, and CDAA 
22-week mice. Data are presented as means ± SEM. *P <0.05 compared with the control 
0-week mice; ##P <0.01 compared with the control 22-week mice. n ≥ 3 for all groups. 
Fifteen random fields were analyzed for each group (×10 000 magnification). 
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Figure 6: (a) Histopathological images of livers from control 8-week, choline-deficient, 
L-amino acid-defined (CDAA) 8-week, and recovery 4-week mice (8 weeks of CDAA 
feeding followed by an additional 4 weeks of standard diet). Hematoxylin and eosin 
(H&E) staining (top row; bars = 100 μm), Azan staining (middle row; bars = 50 μm), 
and reticulin staining (bottom row; bars = 25 μm) are shown. Arrows indicate 
inflammatory cell infiltration (steatohepatitis). Arrowheads indicate reticulin-positive 
areas (type III collagen) in the intralobular lesions. Asterisks indicate dead hepatocytes 
with crystallized lipid droplets. pv, portal vein; cv, central vein. (b) Nonalcoholic fatty 
liver disease activity scores (steatosis, inflammation, and ballooning) and fibrosis stage 
in control 8-week, CDAA 8-week, and recovery 4-week mice. Data are presented as 
means ± SEM. **P <0.01 compared with the control mice; #P <0.05 compared with the 
CDAA 8-week mice; ##P <0.01 compared with the CDAA 8-week mice; n ≥ 5 for all 
groups. N.D, not detected. (c) Scanning electron microscopic images of liver sinusoidal 
endothelial cells in control 8-week, CDAA 8-week, and recovery 4-week mice. 
Arrowheads indicate fenestrae grouped into sieve plates. Bars = 1 μm. (d) Porosity in 
control 8-week, CDAA 8-week, and recovery 4-week mice. Data are presented as means 
± SEM. *P <0.05 compared with the control mice; #P <0.05 compared with the CDAA 
8-week mice. n ≥ 3 for all groups. Fifteen random fields were analyzed for each group 
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(×10 000 magnification). 
 
Figure 7: (a) Macroscopic photographs of livers from control 8-week, high fat diet 
(HFD) 8-week, and HFD 22-week mice. (b) Histopathological images of livers from 
control, HFD 8-week, and HFD 22-week mice. Hematoxylin and eosin (H&E) staining 
(top row; bars = 100 μm), Azan staining (middle row; bars = 50 μm), and reticulin 
staining (bottom row; bars = 25 μm) are shown. The arrow indicates inflammatory cell 
infiltration (steatohepatitis). Arrowheads indicate reticulin-positive areas (type III 
collagen) in the intralobular regions. pv, portal vein; cv, central vein. (c) Nonalcoholic 
fatty liver disease activity scores (steatosis, inflammation, and ballooning) and fibrosis 
stage in control 8-week, choline-deficient, L-amino acid-defined (CDAA) 8-week, and 
HFD 8-week mice. Data are presented as means ± SEM. **P <0.01 compared with the 
control mice. n ≥ 5 for all groups. N.D, not detected. (d) Nonalcoholic fatty liver disease 
activity score and fibrosis stage in control 22-week, CDAA 22-week, and HFD 22-week 
mice. Data are presented as means ± SEM. *P <0.05 compared with the control mice. 
**P <0.01 compared with the control mice. n ≥ 5 for all groups. N.D, not detected. (e) 
Scanning electron microscopic images of liver sinusoidal endothelial cells in HFD 
8-week, HFD 22-week, CDAA 8-week, and CDAA 22-week mice. Arrowheads indicate 
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fenestrae grouped into sieve plates. Asterisks indicate collagen deposits in the space of 
Disse. Bars = 1 μm. (f) Porosity in control, HFD, and CDAA mice after 8 and 22 weeks. 
Data are presented as means ± SEM. *P <0.05 compared with the control 22-week mice; 
#P <0.05 compared with the HFD 22-week mice; ##P <0.01 compared with the HFD 
8-week mice. n ≥ 3 for all groups. Fifteen random fields were analyzed for each group 
(×10 000 magnification). 
Table 1. Phenotypic and biochemical findings
Control 8 weeks HFD 8 weeks CDAA 8 weeks Recovery 4 weeks
Body weight (g)             27.5 ± 0.7           40.4 ± 1.3*             26.9 ± 0.5              30.3 ± 1.4
#
Liver/body weight (%)             4.87 ± 0.32           4.34 ± 0.20             6.04 ± 0.84*              4.89 ± 0.26
#
Spleen/body weight (%)             0.30 ± 0.01           0.20 ± 0.01*             0.41 ± 0.03*              0.49 ± 0.08
#
Epididymal/body fat (%)             1.32 ± 0.28           5.75 ± 0.26*             1.99 ± 0.30*              2.11 ± 0.33
ALT (IU/L)             64.7 ± 21.5           46.3 ± 12.3           162.0 ± 19.4*              26.5 ± 5.4
#
ALP (IU/L)           234.2 ± 13.6         142.7 ± 11.7*           364.3 ± 14.0*            213.7 ± 14.6
#
Cholesterol (mg/dl)             57.6 ± 4.6         125.1 ± 8.4*             74.8 ± 4.8*              69.7 ± 8.2
Triglycerides (mg/dl)             68.2 ± 7.3           44.1 ± 7.7*             37.2 ± 1.2*              36.0 ± 5.5
Free fatty acids (mg/dl)           142.2 ± 28.5         328.7 ± 30.9*            137.2± 12.1            278.0 ± 64.1
#
Bilirubin (mg/dl)             0.02 ± 0.01           0.05 ± 0.004*             0.11 ± 0.01*              0.04 ± 0.02
#
Glucose (mg/dl)           165.4 ± 7.1         251.3 ± 29.1*           203.0 ± 6.1*            162.0 ± 14.1
#
Control 22 weeks HFD 22 weeks CDAA 22 weeks
Body weight (g)             35.1 ± 2.1           53.5 ± 1.7*             28.6 ± 1.4*
Liver/body weight (%)             4.04 ± 0.15           5.96 ± 0.24*             7.24 ± 0.39*
Spleen/body weight (%)             0.29 ± 0.02           0.24 ± 0.01*             0.48 ± 0.03*
Epididymal/body fat (%)             3.87 ± 0.46           5.10 ± 0.38*             1.92 ± 0.41*
ALT (IU/L)             33.8 ± 8.3         148.7 ± 26.1*             45.2 ± 15.2
ALP (IU/L)           160.5 ± 8.1         183.0 ± 24.0           300.4 ± 176.3
Cholesterol (mg/dl)             84.3 ± 6.7         210.0 ± 22.2*             56.8 ± 14.9
Triglycerides (mg/dl)             58.3 ± 11.7           28.3 ± 3.9*             22.7 ± 4.2*
Free fatty acids (mg/dl)           380.0 ± 102.3         280.3 ± 51.3           363.5 ± 91.0
Bilirubin (mg/dl)             0.03 ± 0.01           0.01 ± 0.003*             0.14 ± 0.09*
Glucose (mg/dl)           187.0 ± 31.3         241.3 ± 36.7*           170.0 ± 15.8
Results are presented as means ± SEM (n ≥ 4 for each group). 
HFD: high fat diet; CDAA; choline-deficient L-amino acid-defined diet; 
ALT: alanine aminotransferase; ALP: alkaline phosphatase.
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Supplementary Figure 1: Transmission electron microscopic images of liver 
sinusoidal endothelial cells (LSECs) in control and choline-deficient, L-amino acid-
defined (CDAA) 4-week mice. Arrowheads indicate fenestrae. The arrow indicates 
thickened and defenestrated LSECs. The asterisk indicates collagen deposits in 
the space of Disse. Bar = 1 μm. S, sinusoid lumen; SD, space of Disse.









Supplementary Figure 2: Scanning electron microscopic images of Kupffer 
cells (top row), hepatic stellate cells (HSCs) (bottom left panel), and collagen 
deposits in the space of Disse (bottom right panel) in control and choline-
deficient, L-amino acid-defined (CDAA) 4-week mice. Arrowheads indicate an 
extended pseudopod of Kupffer cell. The uneven surface of the HSC indicates 
intracellular storing of lipid droplets such as vitamin A. The asterisk indicates 
collagen deposits in the space of Disse. Bar = 5 μm. HSC, hepatic stellate 





Supplementary Figure 3: Macroscopic photograph (top panel), hematoxylin 
and eosin staining (bottom left panel), and Azan staining (bottom right panel) of 
livers from choline-deficient, L-amino acid-defined (CDAA) 22-week mice. 
Asterisks indicate hepatocellular adenomas. The dashed lines depict the 
borders between the hepatocellular adenoma and non-neoplastic parenchyma. 
Bar = 200 μm.
CDAA 22 w






Supplementary Figure 4: Toluidine blue staining of resin-embedded liver sections for 
control 8-week, choline-deficient, L-amino acid-defined (CDAA) 8-week, and recovery 
4-week (8 weeks of CDAA feeding followed by an additional 4 weeks of standard diet 
feeding) mice. Arrowheads indicate quiescent hepatic stellate cells (lipid storing cells) 
in the space of Disse. Arrows indicate activated hepatic stellate cells (myofibroblasts, 
spindle-shaped collagen producing cells). Bar = 10 μm. LD, lipid droplet.







Supplementary Figure 5: Transmission electron microscopic images of livers of 
high fat diet (HFD) 8-week and HFD 22-week mice. Arrowheads indicate fenestrae. 
Arrows indicate small lipid particles. The asterisk indicates collagen deposits in 
the space of Disse. Bar = 500 nm. S, sinusoid lumen; SD, space of Disse.









Supplementary Figure 6: Transmission electron microscopic images of livers in 
choline-deficient, L-amino acid-defined (CDAA) 4-week (bar = 500 nm), CDAA 8-
week (bar = 2 μm), CDAA 22-week (top right panel: bar = 5 μm, bottom panel: bar 
= 1 μm), and recovery 4-week (8 weeks of CDAA feeding followed by an additional 
4 weeks of standard diet feeding: bar = 1 μm) mice. Black arrows indicate enlarged 
endoplasmic reticulum. Black arrowheads indicate autophagosomes and 
lysosomes (high-density organelles). White arrowheads indicate loss of microvilli in 
the bile canaliculus. White arrows indicate deformed mitochondria. The asterisk 










Supplementary Figure 7: Transmission electron microscopic images of livers in high 
fat diet (HFD) 8-week (bar = 1 μm) and HFD 22-week (top right panel: bar = 500 nm, 
bottom left panel: bar = 5 μm, bottom right panel: bar = 500 nm) mice. A white arrow 
indicates a deformed mitochondrion. Black arrows indicate enlarged endoplasmic 
reticula. Black arrowheads indicate autophagosomes and lysosomes (high-density 
organelles). Hepatocyte nuclei and a bile canaliculus show normal appearance. N, 
nucleus of hepatocyte; LD, lipid droplet; BC, bile canaliculus.
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